Clinical trial NCT03018587: Feasibility Study of the TruSculpt Radiofrequency Device
Official title: Feasibility Study of the TruSculpt Radiofrequency Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tissue Tightening
Lead sponsor: Cutera Inc.
Sponsor class: INDUSTRY
First posted: 2017-01-12
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A single-center, prospective, open-label feasibility study of the truSculpt radiofrequency device.

Detailed description: A single-center, prospective, open-label study to evaluate the safety and efficacy of the Cutera truSculpt radiofrequency device for optimal delivery of thermal energy to the skin.

Eligibility criteria: Inclusion Criteria:

1. Male or Female, 18 to 70 years of age (inclusive)
2. Fitzpatrick Skin Type I - VI
3. Has visible fat bulges,skin laxity, or cellulite in the treatment area
4. Non-smoking for at least 6 months and willing to refrain from smoking for the duration of the study.
5. Subject must agree to not undergo any other procedure(s) in the treatment area during the study period.
6. Subject must be able to read, understand and sign the Informed Consent Form.
7. Subject must adhere to the follow-up schedule and study instructions.
8. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
9. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant.

Exclusion Criteria:

1. Participation in a clinical trial of another device or drug in the target area during the study period.
2. Has a pacemaker, internal defibrillator, implantable cardioverter-defibrillator, nerve stimulator implant, cochlear implant or any other electronically, magnetically or mechanically activated implant.
3. Has metal implant(s) within the body that is local to the treatment area, such as surgical clips, plates and screws, intrauterine device (IUD), artificial heart valves or artificial joints.
4. Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, peripheral vascular disease or pertinent neurological disorders.
5. Diagnosed or documented immune system disorders.
6. History of any disease or condition that could impair wound healing.
7. History of diseases stimulated by heat, such as recurrent herpes zoster in the treatment area, unless treatment is conducted following a prophylactic regimen.
8. Infection, dermatitis, rash or other skin abnormality in the target area.
9. Currently undergoing systemic chemotherapy or radiation treatment for cancer, or history of treatment in the target area within 3 months of study participation.
10. Pregnant or currently breastfeeding.
11. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Primary outcomes:
measure: Investigator Assessment of Improvement
timeFrame: 12 weeks post-treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Brisbane
country: United States
facility: Cutera Research Center
state: California
Study officials:
affiliation: Principal Investigator
name: Stephen Ronan, M.D.
role: PRINCIPAL_INVESTIGATOR
References: